U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417189) titled 'A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )' on Jan. 28.
Brief Summary: This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
Study Start Date: March 20
Study Type: INTERVENTIONAL
Condition:
Solid Tumors, Adult
Intervention:
DRUG: ABSK141-400mg
In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 400mg administration. T...